当前位置:科学网首页 > 小柯机器人 >详情
小剂量阿司匹林可预防单胎妊娠初产妇早产
作者:小柯机器人 发布时间:2020/2/7 9:38:05

美国克里斯蒂安娜护理健康系统Matthew K Hoffman研究组的最新研究提出了低剂量的阿司匹林可预防单胎妊娠初产妇早产。相关论文于2020年1月25日发表在《柳叶刀》杂志上。

早产依然是新生儿死亡的常见原因之一,中低收入国家负担较重。低剂量阿司匹林预防子痫前期的荟萃分析表明,孕16周前服用阿司匹林可降低早产发生率。

2016年3月23日至2018年6月30日,研究组进行了一项随机、多国家、双盲、安慰剂对照、低剂量阿司匹林试验,在印度、刚果民主共和国、危地马拉、肯尼亚、巴基斯坦和赞比亚的7个社区点招募了11976名怀孕6周0天至13周6天的单胎初产妇,年龄为14-40岁。将其按1:1随机分组,其中5990名孕妇口服小剂量阿司匹林,5986名孕妇口服安慰剂。早产定义为孕37周前分娩。

阿司匹林组有11.6%的孕妇在孕37周前早产,安慰剂组有13.1%,相对风险为0.89,差异显著。阿司匹林组中,围产期死亡率、胎儿流失(孕16周后至产后7天前婴儿死亡)、早期早产(孕34周前分娩)和妊娠期高血压孕妇孕34周前分娩的发生率均显著低于安慰剂组。两组间孕产妇和新生儿其他不良事件的发生率相差不大。

总之,在中低收入国家单胎妊娠初产妇群体中,孕6周0天至孕13周6天开始服用低剂量阿司匹林可降低孕37周前早产的发生率,并降低围产儿死亡率。

附:英文原文

Title: Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial

Author: Matthew K Hoffman, Shivaprasad S Goudar, Bhalachandra S Kodkany, Mrityunjay Metgud, Manjunath Somannavar, Jean Okitawutshu, Adrien Lokangaka, Antoinette Tshefu, Carl L Bose, Abigail Mwapule, Musaku Mwenechanya, Elwyn Chomba, Waldemar A Carlo, Javier Chicuy, Lester Figueroa, Ana Garces, Nancy F Krebs, Saleem Jessani, Farnaz Zehra, Sarah Saleem, Robert L Goldenberg, Kunal Kurhe, Prabir Das, Archana Patel, Patricia L Hibberd, Emmah Achieng, Paul Nyongesa, Fabian Esamai, Edward A Liechty, Norman Goco, Jennifer Hemingway-Foday, Janet Moore, Tracy L Nolen, Elizabeth M McClure, Marion Koso-Thomas, Menachem Miodovnik, R Silver, Richard J Derman, Emmah Achieng, Melissa Bauserman, Carl Bose, Sherri Bucher, Waldemar Carlo, Javier Chicuy, Elwyn Chomba, Prabir Das, Richard Derman, Fabian Esamai, Lester Figueroa, Ana Garces, Noman Goco, Robert Goldenberg, Shivaprasad Goudar, Jennifer Hemingway-Foday, Patricia Hibberd, Matthew Hoffman, Saleem Jessani, Nancy Krebs, Bhalachandra Kodkany, Marion Koso-Thomas, Kunal Kurhe, Edward Liechty, Adrien Lokangaka, Emily MacGuire, Elizabeth McClure, Mrityunjay Metgud, Menachem Miodovnik, Janet Moore, Abigail Mwapule, Musaku Mwenechanya, Farnaz Naqvi, Seemab Naqvi, Robert Nathan, Tracy Nolen, Paul Nyongesa, Jean Okitawutshu, Suchita Parepalli, Archana Patel, Sarah Saleem, Robert Silver, Manjunath Somannavar, Zahid Soomro, Antoinette Tshefu, Dennis Wallace, Farnaz Zehra

Issue&Volume: 2020/01/25

Abstract:

Background

Preterm birth remains a common cause of neonatal mortality, with a disproportionately high burden in low-income and middle-income countries. Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation.

Methods

ASPIRIN was a randomised, multicountry, double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of pregnancy, in nulliparous women with an ultrasound confirming gestational age and a singleton viable pregnancy. Participants were enrolled at seven community sites in six countries (two sites in India and one site each in the Democratic Republic of the Congo, Guatemala, Kenya, Pakistan, and Zambia). Participants were randomly assigned (1:1, stratified by site) to receive aspirin or placebo tablets of identical appearance, via a sequence generated centrally by the data coordinating centre at Research Triangle Institute International (Research Triangle Park, NC, USA). Treatment was masked to research staff, health providers, and patients, and continued until 36 weeks and 7 days of gestation or delivery. The primary outcome of incidence of preterm birth, defined as the number of deliveries before 37 weeks' gestational age, was analysed in randomly assigned women with pregnancy outcomes at or after 20 weeks, according to a modified intention-to-treat (mITT) protocol. Analyses of our binary primary outcome involved a Cochran-Mantel-Haenszel test stratified by site, and generalised linear models to obtain relative risk (RR) estimates and associated confidence intervals. Serious adverse events were assessed in all women who received at least one dose of drug or placebo. This study is registered with ClinicalTrials.gov, NCT02409680, and the Clinical Trial Registry-India, CTRI/2016/05/006970.

Findings

From March 23, 2016 to June 30, 2018, 14?361 women were screened for inclusion and 11?976 women aged 14–40 years were randomly assigned to receive low-dose aspirin (5990 women) or placebo (5986 women). 5780 women in the aspirin group and 5764 in the placebo group were evaluable for the primary outcome. Preterm birth before 37 weeks occurred in 668 (11·6%) of the women who took aspirin and 754 (13·1%) of those who took placebo (RR 0·89 [95% CI 0·81 to 0·98], p=0·012). In women taking aspirin, we also observed significant reductions in perinatal mortality (0·86 [0·73–1·00], p=0·048), fetal loss (infant death after 16 weeks' gestation and before 7 days post partum; 0·86 [0·74–1·00], p=0·039), early preterm delivery (<34 weeks; 0·75 [0·61–0·93], p=0·039), and the incidence of women who delivered before 34 weeks with hypertensive disorders of pregnancy (0·38 [0·17–0·85], p=0·015). Other adverse maternal and neonatal events were similar between the two groups.

Interpretation

In populations of nulliparous women with singleton pregnancies from low-income and middle-income countries, low-dose aspirin initiated between 6 weeks and 0 days of gestation and 13 weeks and 6 days of gestation resulted in a reduced incidence of preterm delivery before 37 weeks, and reduced perinatal mortality.

DOI: 10.1016/S0140-6736(19)32973-3

Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32973-3/fulltext

期刊信息

LANCET:《柳叶刀》,创刊于1823年。隶属于爱思唯尔出版社,最新IF:59.102
官方网址:http://www.thelancet.com/
投稿链接:http://ees.elsevier.com/thelancet